Novartis is sharpening its India strategy as a pure-play innovator focused on core therapy areas such as cardiovascular disease, oncology and immunology after divesting its stake in its listed arm earlier this year.
Speaking to Times of India, Novartis India country president and managing director Amitabh Dube said India is increasingly contributing to nearly every molecule the company commercialises globally and is moving up the value chain with early-stage scientific discovery and Phase I studies beginning to take shape in the country.
In February, Novartis announced the sale of its 71% stake in listed subsidiary Novartis India for around Rs 1,446 crore to private equity investors led by ChrysCapital. The company retained its unlisted arm, Novartis Healthcare, to drive its innovative medicines business in India.
Dube told TOI that Novartis recently initiated Phase I clinical research in Ahmedabad and will continue Phase II and III programmes across key therapeutic areas. He added that India played a major role in several global therapies, including Coartem Baby, cardiovascular drug Inclisiran (Sybrava), and prostate cancer therapy Pluvicto.
Novartis operates one of its three global development hubs in India, alongside Basel and the US, with centres in Hyderabad and Mumbai.
“Our philosophy has been to transform into a pure-play innovative medicines company,” Dube told TOI, adding that Novartis remains committed to India with over 9,000 employees and plans to launch more new molecules in the coming years.
Speaking to Times of India, Novartis India country president and managing director Amitabh Dube said India is increasingly contributing to nearly every molecule the company commercialises globally and is moving up the value chain with early-stage scientific discovery and Phase I studies beginning to take shape in the country.
In February, Novartis announced the sale of its 71% stake in listed subsidiary Novartis India for around Rs 1,446 crore to private equity investors led by ChrysCapital. The company retained its unlisted arm, Novartis Healthcare, to drive its innovative medicines business in India.
Dube told TOI that Novartis recently initiated Phase I clinical research in Ahmedabad and will continue Phase II and III programmes across key therapeutic areas. He added that India played a major role in several global therapies, including Coartem Baby, cardiovascular drug Inclisiran (Sybrava), and prostate cancer therapy Pluvicto.
Novartis operates one of its three global development hubs in India, alongside Basel and the US, with centres in Hyderabad and Mumbai.
“Our philosophy has been to transform into a pure-play innovative medicines company,” Dube told TOI, adding that Novartis remains committed to India with over 9,000 employees and plans to launch more new molecules in the coming years.
